181 related articles for article (PubMed ID: 37877561)
1. Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview.
Singh NK; Ramamourthy B; Hage N; Nagaraju S; Kappagantu KM
Curr Radiopharm; 2024; 17(1):2-6. PubMed ID: 37877561
[TBL] [Abstract][Full Text] [Related]
2. Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer.
Bohinc BN; Perkins JM
Curr Opin Oncol; 2014 Jan; 26(1):31-5. PubMed ID: 24225414
[TBL] [Abstract][Full Text] [Related]
3. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
4. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
Patel SS; Goldfarb M
J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
[TBL] [Abstract][Full Text] [Related]
5. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.
Padma S; Sundaram PS
J Cancer Res Ther; 2016; 12(3):1109-1113. PubMed ID: 28054519
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
8. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine therapy.
Lee SL
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):420-8. PubMed ID: 22914564
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
11. The role of radioactive iodine in the management of patients with differentiated thyroid cancer - An oncologic surgical perspective.
Nixon IJ; Shah JP; Zafereo M; Simo RS; Hay ID; Suárez C; Zbären P; Rinaldo A; Sanabria A; Silver C; Mäkitie A; Vander Poorten V; Kowalski LP; Shaha AR; Randolph GW; Ferlito A
Eur J Surg Oncol; 2020 May; 46(5):754-762. PubMed ID: 31952928
[TBL] [Abstract][Full Text] [Related]
12. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
14. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer.
Uno A; Takeda H; Mori M; Yamamoto Y; Takenaka Y; Enomoto K; Takeda N
J Med Invest; 2023; 70(1.2):17-21. PubMed ID: 37164716
[TBL] [Abstract][Full Text] [Related]
15. Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center.
Thiagarajan S; Yousuf A; Shetty R; Dhar H; Mathur Y; Nair D; Basu S; Patil A; Kane S; Ghosh-Laskar S; Chaukar D
Eur Arch Otorhinolaryngol; 2020 Jun; 277(6):1807-1814. PubMed ID: 32170421
[TBL] [Abstract][Full Text] [Related]
16. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
[TBL] [Abstract][Full Text] [Related]
17. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Lassmann M; Reiners C; Luster M
Endocr Relat Cancer; 2010 Sep; 17(3):R161-72. PubMed ID: 20448022
[TBL] [Abstract][Full Text] [Related]
19. [CME: Radioactive iodine therapy in thyroid cancer].
Steinert HC; Aberle S
Praxis (Bern 1994); 2015 Nov; 104(23):1235-43; quiz 1244-5. PubMed ID: 26558927
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer.
Konishi K; Ishiba R; Ikenohira T; Asao T; Hirata M; Ohira K; Komatsu T; Sawada M; Tanahashi Y; Goshima S; Magata Y; Nakamura K
Ann Nucl Med; 2021 Feb; 35(2):159-166. PubMed ID: 33387279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]